A groundbreaking clinical trial in Australia is exploring the potential of a new CBD-based capsule to combat insomnia. Conducted by Melbourne biotech company Avecho, the trial seeks to recruit 519 participants suffering from episodic insomnia—sleep disturbances lasting one to three months. The capsule, taken once daily before bed, contains cannabidiol (CBD), a compound known for its calming properties. Unlike traditional cannabis products, this is a pharmaceutical-grade, synthetic medication designed to mimic the soothing effects of cannabis without being an oil or medicinal cannabis.

Avecho’s CEO, Dr. Paul Gavin, emphasized the study’s significance, noting it will compare the effects of CBD against a placebo across three treatment groups. The trial’s success could lead to approval by the Therapeutic Goods Administration, offering a new remedy for the 10% of adults grappling with persistent insomnia. For more details, visit the full article on 9News.